Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deals Of The Week: Eisai/Epizyme, AstraZeneca/Galderma, Evotec/Harvard

Executive Summary

Each week, “The Pink Sheet” presents commentary on some of the week’s most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at http://invivoblog.blogspot.com.
Advertisement

Related Content

Evotec Buys Bionamics For Shortcut To German Academic Gems
Deals of the Week: AstraZeneca’s Neuroscience Deals, Verastem/Pfizer, Alnylam/Ascletis
A New Collaborative Model? Janssen Joins Evotec And Harvard To Advance Regenerative Diabetes Projects
With Vicept Buy, Allergan Gains Rosacea Treatment Under Development
With Vicept Buy, Allergan Gains Rosacea Treatment Under Development
Vicept Acquired By Allergan For $75M Upfront
Valeant Adds To Dermatology Business By Acquiring Sanofi's Dermik For $425 Million
Buoyed By Broad Labeling, HGSI Plans To Launch Benlysta In Two Weeks
Buoyed By Broad Labeling, HGSI Plans To Launch Benlysta In Two Weeks

Topics

Advertisement
UsernamePublicRestriction

Register

PS053205

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel